Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19
| Autor: | Yuli Guzman-Prado |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Pneumonia Viral coronavirus medicine.disease_cause Article Betacoronavirus Chloroquine Internal medicine Pandemic Humans Medicine Pandemics Coronavirus Cardiovascular safety biology SARS-CoV-2 business.industry cardiovascular COVID-19 Hydroxychloroquine biology.organism_classification Virology COVID-19 Drug Treatment Cardiology Coronavirus Infections business Cardiology and Cardiovascular Medicine medicine.drug |
| Zdroj: | The American Journal of Cardiology |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2020.06.003 |
| Popis: | Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure and mortality have been reported with the use of these drugs. It is important to have a knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect